Adrien Lemaitre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Adrien Lemaitre has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Vincent Roule
Department of Cardiology, University Hospital of Caen Normandie, Normandie University, France (V.R., F.B.).
3 shared publications - Fabien Labombarda
Service de Cardiologie, CHU de Caen, Université de Caen Normandie, F-14000 Caen, France
2 shared publications - Farzin Beygui
Department of Cardiology, University Hospital of Caen Normandie, Normandie University, France (V.R., F.B.).
2 shared publications - Joachim Alexandre
Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE, Biology-Research Building, Avenue de la Côte de Nacre, F-14000 CAEN, France; Caen-Normandy University Hospital, PICARO Cardio-Oncology Program, Department of Pharmacology, Biology-Research Building , Avenue de la Côte de Nacre, F-14000 CAEN
2 shared publications - Alain Lebon
Department of Cardiology, CHU de Caen, Avenue de la côte de nacre, 14000 Caen, France
1 shared publication - Audrey Emmanuelle Dugué
Caen University Hospital, Department of Biostatistics and Clinical Research, Caen F-14000, France
1 shared publication
Latest Publications
- 28 April 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (6) , 1191-1199
Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies—Analysis of the WHO Pharmacovigilance Database
Purpose While statins and antiplatelet therapies are largely prescribed together worldwide, limited information is available on the safety of their association regarding rhabdomyolysis occurrence. We aimed to assess the reporting of rhabdomyolysis in patients treated with a combination of statin and antiplatelet therapy, compared to statin alone. Methods We used the World Health Organization pharmacovigilance database (VigiBase®) to compare the rhabdomyolysis reporting between statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin) plus antiplatelet therapy (acetylsalicylic acid, clopidogrel, prasugrel and ticagrelor) groups versus statin alone groups, for each statin and antiplatelet therapy. Study setting was restricted to patients aged 45 or older, including reports up until 1st September, 2021. We computed reporting Odds-Ratio (ROR) and their 95% confidence interval (CI) to quantify the disproportionality between groups, adjusted on age and sex. Results Among the 11,431,708 reports of adverse reactions, we extracted 9,489 cases of rhabdomyolysis in patients treated with statins, of whom 2,464 (26%) were also treated with antiplatelet therapy. The reporting of rhabdomyolysis was increased when ticagrelor was associated with atorvastatin (ROR 1.30 [1.02–1.65]) or rosuvastatin (ROR 1.90 [1.42–2.54]) compared to the respective statin alone but did not change when aspirin, clopidogrel or prasugrel were considered. Conclusion Rhabdomyolysis reporting was increased when ticagrelor -but not other antiplatelet agents- was notified with the most prescribed statins in practice. This finding needs to be considered by physicians especially in high-risk patients.
- 28 April 2023
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (6) , 1191-1199
Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies—Analysis of the WHO Pharmacovigilance Database
Purpose While statins and antiplatelet therapies are largely prescribed together worldwide, limited information is available on the safety of their association regarding rhabdomyolysis occurrence. We aimed to assess the reporting of rhabdomyolysis in patients treated with a combination of statin and antiplatelet therapy, compared to statin alone. Methods We used the World Health Organization pharmacovigilance database (VigiBase®) to compare the rhabdomyolysis reporting between statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and simvastatin) plus antiplatelet therapy (acetylsalicylic acid, clopidogrel, prasugrel and ticagrelor) groups versus statin alone groups, for each statin and antiplatelet therapy. Study setting was restricted to patients aged 45 or older, including reports up until 1st September, 2021. We computed reporting Odds-Ratio (ROR) and their 95% confidence interval (CI) to quantify the disproportionality between groups, adjusted on age and sex. Results Among the 11,431,708 reports of adverse reactions, we extracted 9,489 cases of rhabdomyolysis in patients treated with statins, of whom 2,464 (26%) were also treated with antiplatelet therapy. The reporting of rhabdomyolysis was increased when ticagrelor was associated with atorvastatin (ROR 1.30 [1.02–1.65]) or rosuvastatin (ROR 1.90 [1.42–2.54]) compared to the respective statin alone but did not change when aspirin, clopidogrel or prasugrel were considered. Conclusion Rhabdomyolysis reporting was increased when ticagrelor -but not other antiplatelet agents- was notified with the most prescribed statins in practice. This finding needs to be considered by physicians especially in high-risk patients.
- Open Access
- 12 June 2020
- Published by Hindawi Limited in Journal of Interventional Cardiology
- Vol. 2020, 1-7
Evaluation of Left Main Coronary Artery Using Optical Frequency Domain Imaging and Its Pitfalls
Objectives. We aimed to assess the quality of optical frequency domain imaging (OFDI) of the left main (LM) arterial wall and describe and analyse potential artefacts in this setting.Background. OFDI is increasingly used to assess ambiguous lesions and optimize LM percutaneous coronary intervention. However, its ability to provide artefact-free high-quality images of coronary ostia and large segments such as the LM remains uncertain.Methods. We included 42 consecutive patients who underwent OFDI, including LM imaging. Each OFDI frame was subdivided into four quadrants and analysed. The number of quadrants with artifacts was calculated within the proximal, mid, and distal LM and the first 5 mm of the left anterior descending artery (LAD) and/or left circumflex artery (LCX).Results. The quadrants analysis showed an overall artifact rate of 8.9%, mostly out-of-field (45.1%) or residual blood (44.7%) artefacts. Most artifacts were located in the proximal LM (18.6%) with a stepwise reduction of artifact rates towards distal segments (mid LM 5.8%; distal LM 3.6%, ostial LAD 2.6%, and ostial LCX 0%;p90% of the quadrants of the LM and the ostia of its bifurcation branches. However, artifacts mainly located in the proximal LM and decreasing distally in a stepwise fashion should be considered in the interpretation of OFDI in this setting.
- 12 June 2020
- Published by Hindawi Limited in Journal of Interventional Cardiology
- Vol. 2020, 1-7
Open AccessEvaluation of Left Main Coronary Artery Using Optical Frequency Domain Imaging and Its Pitfalls
Objectives. We aimed to assess the quality of optical frequency domain imaging (OFDI) of the left main (LM) arterial wall and describe and analyse potential artefacts in this setting.Background. OFDI is increasingly used to assess ambiguous lesions and optimize LM percutaneous coronary intervention. However, its ability to provide artefact-free high-quality images of coronary ostia and large segments such as the LM remains uncertain.Methods. We included 42 consecutive patients who underwent OFDI, including LM imaging. Each OFDI frame was subdivided into four quadrants and analysed. The number of quadrants with artifacts was calculated within the proximal, mid, and distal LM and the first 5 mm of the left anterior descending artery (LAD) and/or left circumflex artery (LCX).Results. The quadrants analysis showed an overall artifact rate of 8.9%, mostly out-of-field (45.1%) or residual blood (44.7%) artefacts. Most artifacts were located in the proximal LM (18.6%) with a stepwise reduction of artifact rates towards distal segments (mid LM 5.8%; distal LM 3.6%, ostial LAD 2.6%, and ostial LCX 0%;p90% of the quadrants of the LM and the ostia of its bifurcation branches. However, artifacts mainly located in the proximal LM and decreasing distally in a stepwise fashion should be considered in the interpretation of OFDI in this setting.
- Open Access
- 1 January 2013
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 15 (1) , 12
Scar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease
- 1 January 2013
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 15 (1) , 12
Open AccessScar extent evaluated by late gadolinium enhancement CMR: a powerful predictor of long term appropriate ICD therapy in patients with coronary artery disease